Ubicación del inventario

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Sujeto a disponibilidad

Documentation

Descargar MSDS

Descargar COA de muestra

Incluye: HPLC, MASS/LC-MS, RMN de 1H, FT-IR, potencia, informe de elucidación estructural (SER) y datos analíticos adicionales según el producto.

122861-53-4Doxycycline EP Impurity F

● En Stock

Número de catálogo:	VL159002
N.º CAS:	122861-53-4
Fórmula mol.::	C23H25NO8
Peso mol.::	443.45 g/mol

Solicitar cotización

Añadir a la lista de RFQ

Información adicional sobre el CAS 122861-53-4

Fármaco de origen

Doxycycline

Nombre IUPAC

(4S,4aR,5S,5aR,6R,12aS)-2-acetyl-4-(dimethylamino)- 3,5,10,12,12a-pentahydroxy-6-methyl-4a,5a,6,12a-tetrahydrotetracene-1,11(4H,5H)-dione

Sinónimos farmacopeicos

2-Acetyl 2-Decarbamoyl Doxycycline; Doxycycline Related Compound F

Otros sinónimos

1,11(4H,5H)-Naphthacenedione, 2-acetyl-4-(dimethylamino)-4a,5a,6,12a-tetrahydro-3,5,10,12,12a-pentahydroxy-6-methyl-, (4S,4aR,5S,5aR,6R,12aS)-

Smile

O=C1C(C(C)=O)=C(O)[C@@H](N(C)C)[C@@]2([H])[C@]1(O)C(O)=C(C(C3=C(O)C=CC=C3[C@@H]4C)=O)[C@]4([H])[C@@H]2O

InChI

InChI=1S/C23H25NO8/c1-8-10-6-5-7-11(26)14(10)18(27)15-12(8)19(28)16-17(24(3)4)20(29)13(9(2)25)21(30)23(16,32)22(15)31/h5-8,12,16-17,19,26-28,30,32H,1-4H3/t8-,12+,16+,17-,19-,23+/m0/s1

Condición de envío

Ambient Temperature

Characterization Data (Included)

HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, and Structure Elucidation Report (SER).

Datos adicionales de caracterización

QNMR, D2O Exchange, 13C NMR, 13C APT, COSY NMR, NOESY NMR, 15N NMR, HSQC NMR, HMQC NMR, and HMBC NMR. These are available upon request and may be free or subject to additional charges.

Descripción

Doxycycline EP Impurity F, also known in pharmacopoeias as 2-Acetyl 2-Decarbamoyl Doxycycline; Doxycycline Related Compound F, is a highly characterized reference material. It fully complies with stringent regulatory standards, including those set by USP, EMA, JP, and BP. This product is essential for use in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial production of Doxycycline. Moreover, it comes with a detailed Structure Elucidation Report (SER), ensuring its accuracy and reliability for a wide range of analytical applications.

Referencias

‘Smith, kelly, and James J. Leyden. “Safety of Doxycycline and Minocycline: A Systematic Review.” Clinical Therapeutics, vol. 27, no. 9, Sept. 2005, pp. 1329–42, https://doi.org/10.1016/j.clinthera.2005.09.005. ?Saivin, S., and G. Houin. “Clinical Pharmacokinetics of Doxycycline and Minocycline.” Clinical Pharmacokinetics, vol. 15, no. 6, Dec. 1988, pp. 355–66, https://doi.org/10.2165/00003088-198815060-00001 ‘